NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
Zoe CraigJayne SwainEmma BatmanJonathan WadsleyNicholas ReedOlusola FaluyiJudith CaveRohini SharmaIan ChauLucy WallAngela LamarcaR HubnerWasat MansoorDebashis SarkerTim MeyerDavid A CairnsHelen HowardJuan W ValleMairéad G McNamaraPublished in: BMJ open (2020)
ISRCTN10996604, NCT03837977, EudraCT Number: 2017-002453-11.